This review summarizes recent information on the effects of immunomodulatory cytokines on human melanoma cells. The action of interferon (IFN}-alpha, -beta, and -gamma has been extensively examined in melanoma and melanocyte cultures in vitro, and increasing information on the action of other cytokines is now available. All IFNs revealed a dose dependent antiproliferative effect on melanoma cells with the highest growth inhibition caused by IFN-beta. Prolifera tion was also inhibited by interleukin (IL) 1-alpha and -beta, and tumor necrosis factor (TNF}-alpha. For IL-4, both growth-stimulatory and -inhibitory properties have been re ported. Cellular differentiation in terms of melanin synthe sis, formation of dendrite like structures, and antigenic changes was not affected by IFN-alpha or -beta. IFN gamma, however, induced a more dedifferentiated and bio-
other cytokines is now available. All IFNs revealed a dose dependent antiproliferative effect on melanoma cells with the highest growth inhibition caused by IFN-beta. Prolifera tion was also inhibited by interleukin (IL) 1-alpha and -beta, and tumor necrosis factor (TNF}-alpha. For IL-4, both growth-stimulatory and -inhibitory properties have been re ported. Cellular differentiation in terms of melanin synthe sis, formation of dendrite like structures, and antigenic changes was not affected by IFN-alpha or -beta. IFN gamma, however, induced a more dedifferentiated and bio-R ecombinant technology has allowed large scale cyto kine production and thereby provided the facilities for new cancer treatment concepts. The finding of direct antiproliferative effects of different interferons (IFNs) on melanoma cells in vitro focused the attention on these substances as possible antitumor agents for therapeutic pur poses [1, 2) . Additionally, the involvement ofIFNs in the regulation of the immune system and in cellular differentiation has been de scribed [3] [4] [5] . These different mechanisms of action may possibly contribute to the antitumoral activity ofIFNs, which are used today for systemic treatment of metastatic melanoma and are combined for this purpose with different cytokines and cytotoxic drugs [6) . Several new cytokines have been detected and characterized in the last years and some of their effects on melanoma cells have been investigated recently (Table I) . Interleukin (IL) 1, IL-4, tumor ne crosis factor (TNF) alpha, and transforming growth factor (TGF) logically more aggressive phenotype of melanoma cells. His tocompatibility antigen (HLA) class I molecules were found upregulated by all IFN s and by TNF-alpha, associated with a marked increase of melanoma cell lysis by tumor infiltrating lymphocytes in vitro. HLA class II molecules were de novo expressed or enhanced by IFN-gamma and TNF-alpha. The adhesion molecules ICAM-1, LFA-3, and VLA-2 were up regulated by IFN-gamma, TNF-alpha, and IL-1-beta, whereas melanoma-associated antigens were hardly affected by cytokines. It seems that both antiproliferative and immunomodulatory effects may contribute to the antitu moral activity of cytokines in vivo. In vivo application of cyto kines as well as combinations with cytotoxic drugs, therefore, may be promising for future treatment strategies. ] Invest DermatoI100:239S-244S, 1993 beta-1 inhibited melanoma cell proliferation in vitro [7 -13) . IL-6 showed growth-stimulatory properties in murine melanoma cells [14) . The present knowledge on cytokine effects in benign and malignant melanocytes is mainly based on investigations in vitro. So far, there are only few systematic investigations on the different effects of single cytokines on melanoma cells. This review sum marizes the available data on IFNs and other cytokines on the pro liferation, cellular differentiation, the antigenic profile of mela noma cells, and their indirect effects via immune responses of the host.
DIRECT ANTIP ROLIFERATIVE EFFECT S
Interferons The role of IFNs as growth inhibitory compounds for human melanoma cells in vitro is well established. Czamiecki et al described synergistic antiviral and antiproliferative effects of re combinant human IFN-alpha, -beta and -gamma [2) . Both type I and II IFN are capable of inhibiting the proliferation of fresh and long-term cultured melanoma cells either in soft agar or monolayer systems [1, 2, 15, 16) . Contradictory results have been reported on which type of IFN is most effective with respect to antiviral units or molar concentrations. Although some investigators report type II IFN-garnma as the most potent agent [17), we and others found a clearly higher efficiency oflFN-beta compared to both IFN-alpha and IFN-gamma to inhibit the proliferation of established mela noma cell lines (Fig 1) [5, 16) . These effects were predominantly cytostatic. Removal of IFN from the culture medium resulted in a rapid onset of proliferation (Fig 2) . The combination of type I IFNs, IFN-alpha, and IFN-beta, which bind to the same receptor, resulted in subadditive antiproliferative effects, possibly due to decreased binding ofIFN-beta to type I IFN -receptor [16) . On the other hand, combination of type I and II IFN led to a strong synergistic action of both compounds [16) . Comparative studies performed on normal human melanocytes showed a strong antiproliferative activity of IFN-beta and little or no action oflFN-alpha or -gamma [18).
0022-202X/93/S06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. Tumor Necrosis Factor-Alpha No conclusive information exists on the capacity of TNF-alpha to inhibit the proliferation of cultured melanoma cells [9, 13] . Apparently, only a subgroup of melanoma cell lines responded to TNF-alpha, and TNF-alpha, having cytotoxic rather than cytostatic effects, may select in vitro for melanoma cells with enhanced malignancy [13] . In animal models SKMel-28 after a 2-day treatment with rIFN-alpha-2a, nIFN-beta, and rIFN-gamma (100 U/ml) [16] .
239S
TGF-beta prevents cell replication by arresting cells in the GO/G1 phase [25] .
Interleukius Scant information exists on IL-l action on pigment cells. Most melanoma cell lines are resistant to IL-l. IL-lalpha sen sitive cell lines have been described, such as A375 [8, 26] . Mortarini et al found three of nine melanoma cell lines to respond to IL-l beta [9] . The same authors found inhibition of melanoma cell prolifera tion by IL-4 in three of nine cultures tested; however, a slight stimulatory effect was observed in two others. Hoon et al also re ported that incubation of human melanoma cells in vitro with IL-4 resulted in significant inhibition of proliferation [10] . The effects of other cytokines on melanoma cells are unknown so far; there are only two reports on the growth stimulation of murine melanoma cells by IL-6 [14] , and of growth inhibition in melanocyte cultures [20J.
The mode of antiproliferative action of cytokines such as IFNs seems to be cytostatic without clear cytotoxic effects. The growth control is associated with a decreased probability of the cytokine treated cells to enter the cell cycle and an increasing portion remain ing in the Go phase. Possibly, this effect is mediated by increasing levels of (2'-5') oligoadenylate synthetase [27J. Combined cytokine treatment of melanoma cells revealed synergistic antiproliferative effects with IFN-� amma and TNF-alpha or IFN-alpha and IFN gamma [16,28,29J . These synergistic dfects are probably mediated through the induction of cytokine receptors on melanoma cells [29J.
CELLULAR DIFFERENTIATION
The term differentiation has been used to describe processes leading to the expression of phenotypic properties characteristic for func tionally mature cells in vivo. Tnere appears to be an inverse relation ship between the expression of differentiation and malignancy asso ciated properties, even to the extent that induction of differentiation has been proposed as a model for cancer treatment [30J. IFNs are known to induce cellular differentiation in different hematologic malignancies [31 J and, therefore • Crosses indic:ate inhibition of cell ular proliferation as follows: +, little; ++, medium; +++, high. * growth stimulation; and 0, no effect; ND, not done.
deliver melanin to keratinocytes via long dendrites in vivo. The formation of dendrites can also be observed in cell culture, and dendritelike structure formation may be interpreted as a sign indi cating cellular differentiation in melanoma cells [16,33J . Further more, the antigenic phenotype is linked to melanocyte maturation and cellular differentiation and certain antibody-defined mela noma-associated molecules were revealed to be useful markers of melanocytic differentiation [4, 16, 34] .
Interferon-Alpha and -Beta Induction of cellular differentia tion has been investigated in both murine and human melanoma cells. IFNs are so far the only cytokines that were broadly examined with respect to their differentiating effects on melanoma cells. Interferon-Gamma IFN-garnma is a potent inducer of HLA class I antigens on melanoma cells in vitro [4, [36] [37] [38] 40] , similar to type I IFN. In addition, IFN -gamma is able to induce strong expres sion of HLA-DR antigens even in class II negative melanoma cell lines [4, [36] [37] [38] 40] . The capacity of IFN-gamma to induce HLA II antigens is much higher in comparison to type I IFN (up to 3 times for HLA-DR/DP antigens and up to 10 times for HLA-DQ [36] ). HLA-DR is more susceptible to upregulation by IFN-gamma than HLA-DQ or -DP antigens [16, 38, 41, 42] . Different mechanisms are seemingly responsible for the modulation ofHLA-DR on mela noma cells than for the mediation of antiproliferative effects or for the upregulation of HLA-I by IFN-gamma, as shown in experi ments using IFN-gamma resistant melanoma cell lines [43] . Specific modulation by IFN-gamma could be shown for the ICAM-l by several investigators using monoclonal MoAbs directed against dif ferent epitopes of this adhesion molecule, such as MoAbs CL203, CL207, and 84HI0 [16, 44] . For this process de novo RNA and pro tein synthesis are required [44] . Regarding the modulation of MAA expression by IFN-gamma, Houghton et al [4] and Herlyn et al [40] found no modulation of MAA by either type I or type II IFN in contrast to HLA. On the other hand, IFN-garnma reduced the synthesis of both HMW -MAA and of 100-kD MAA [45] . Guiffre et al reported on a novel MAA inducible by gamma-IFN, a 33 to 38 kD glycoprotein expressed on melanoma cells [34] . Expression of p97 has been found enhanced by both type I IFN-alpha and type II IFN-gamma [46] ' We found that IFN-gamma additionally in duced the expression of the progression marker A. Tumor Necrosis Factor-Alpha TNF-alpha has been shown to increase the expression of both HLA-class I and class II DR antigens as well as of ICAM-l on melanoma cells, although it is less potent than IFN-gamma [9, 10, 48] . Maio et al reported that regulation of HLA-DR expression involved both transcriptional and post-tran scriptional mechanisms [48] . TNF-alpha did not influence expres sion of HMW-MAA [48] , but significantly enhanced ganglioside D2 (GD2) expression [10] . Also, it increased the expression of the progression marker VLA-2 antigen and reduced the expression of the early marker K.1.2 [13] .
Interleukins The effects ofILs on the immunophenotype of mel anoma cells in vitro have been far less well investigated. Mortarini et al described borderline changes ofHLA-DR and of MAA expression on various melanoma cell lines incubated with IL-l beta, or IL-4 [9] .
In those experiments, a hierarchy in cytokine effects could be shown, with IFN-gamma being the most potent immunoregulatory agent, followed by TNF-alpha. Similar results with IL-4 were re ported by Hoon et ai, showing the induction ofHLA-1 and II antigens and an elevation of the GM3/GD3 ratio and enhancement of GD2 by IL-4 [10] .
INDIRECT EFFECTS VIA THE IMMUNE RESPONSE OF TH E HOST
Interferon-Alpha and -Beta IFN-alpha is obviously in a posi tion to augment the natural killer (NK) cell activity in vitro and in vivo [49, 50] . Interestingly, an initial and transient decline in blood NK cell activity during the first hours after IFN application has been described that seems to be mediated by suppressor monocytes [51] . An increase of NK activity against melanoma cell lines was only found during the first treatment cycle in melanoma patients, but in subsequent treatment cycles NK activity tended to decrease [52] . Therefore, it remains controversial whether the moderate stim ulation of NK activity by type I IFN s may contribute to any relevant antitumoral activity. Recently, the antitumor/antimetastatic effects of immune cells and their modulation by IFNs has been studied in a murine animal model. Depletion of NK cells, alone or in combina tion with T cells, eliminated the protective effect of IFN treatment; by depletion of CD4-cells alone the protective effect was also elimi nated. These results demonstrate the importance of the interaction of different components of the immune systems and their activation by IFNs [53] .
Interferon-Gamma The enhancement of HLA class I antigens by IFN-gamma correlated with decreased target susceptibility to lysis by NK cells, whereas the ability of tumor infiltrating lympho cytes (TIL) to lyse the cultured tumor target was markedly increased by pre-incubation of the targets with IFN-gamma [54] . It has been proved in an animal model that the expression of HLA class I anti gens is essential for TIL activity [55] . IFN-gamma was shown in a murine model to activate macrophages to kill melanoma rumor targets [56] . IFN-gamma increases the expression of ICAM-l on melanoma cells and the expression of this antigen was found to be associated with an increase of melanoma cell vulnerability to mono cyte-mediated killing [57] .
Tumor Necrosis Factor-Alpha TNF-alpha enhances HLA class I antigen expression and increases the expression ofl CAM-l [54, 57] . Pre-incubation of melanoma cells with TNF-alpha, there fore, induces resistance against NK-cell lysis, increases lysis by TIL and also the sensitivity of these cells to monocyte-mediated killing [54, 57] . Melanoma cells are not only sensitive targets to different cyto k4J,es, but they possess the capacity to produce cytokines them ·selves. IL-l, IL-6, and TGF-beta have been detected to be secreted by cultured melanoma cells [58] [59] [60] [61] . Furthermore, additional growth factors are produced by melanoma cells [62] . The influence of exogenous cytokines on the autocrine production of cytokines by melanoma cells has not yet been examined.
FUTURE PERSPECTIVES OF CYTOKINE
TREATMENT IN MELANOMA Mainly the IFN s have been examined in melanoma treatment. High local tissue concentrations after intralesional application into metas tases of both IFN-alpha and IFN-beta led to a regression of more than 50% of the metastases [63, 64] . Also, after systemic application of IFN -alpha and IFN -beta in over 500 patients, the mean response rates were between 10% and 15% for the different agents [6, 65] . In light of in vitro results, it appeared promising to study the effective ness of IFNs in combination with cytostatic drugs [16] . The results of more than 15 clinical trials have already been published and a number of other clinical studies are under way. Results of in vitro trials showed that type I IFNs may produce antagonistic effects combined with some agents (e.g., cisplatin) and synergistic effects when combined with others (e.g., vindesine and BCNU) [6, 66] . Clinical trials with combined IFN s and cytostatic drug therapy were started a few years ago and have yielded promising initial results. Various investigators reported a response rate of 25% to 30% with a combination of dacarbazine and IFN-alpha [6] . So far, similar re sponse rates have only been achieved by combining three to four cyostatic agents that involved a much higher toxicity [65] . Based on the published results, this therapeutic concept can be considered safe in practice and seems to be a useful alternative to polychemo therapy. Recent reports on multidrug regimens including IFN-alpha re vealed surprisingly high overall response rates of greater than 50%, which belong to the highest response rates ever described for meta static melanoma [6] . Interestingly, the addition of IL-2 to combina tion schedules seemed to augment the response rates further. IL-2 has no direct effects on melanoma cells in vitro, but it transforms precursor lymphocytes into lymphokine activated killer cells and stimulates the capacity to lyse tumor cells resistant to NK cells. Improvement of response rates by the addition of IL-2 is in agree ment with the results of various IL-2 trials in disseminated mela noma in which the best responses were obtained by combining IL-2 and IFN-alpha [67] . Possibly, future therapeutic schedules for meta static melanoma will include combinations of cytotoxic drugs with cytokines showing antiproliferative capacity or enhancement of im munologic mechanisms against melanoma cells. 
